Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinicopathologic characteristics of uterine malignant epithelioid neoplasms with EWSR1::CREM fusion: Report of 2 cases at a novel site with literature review.

Virchows Archiv : an international journal of pathology·2026

Same author

A Little Finger with Long-standing Blue Discolouration and Nail Dystrophy.

Acta dermato-venereologica·2026

Same author

Single-atom loaded BTEA-COF for enhanced visible-light photocatalytic H<sub>2</sub> production: insights from first-principles and real-time TDDFT calculations.

Physical chemistry chemical physics : PCCP·2026

Same author

Environmental behaviors and ecotoxicity of imidaclothiz: a comprehensive review on fate, degradation processes, and ecological risks.

Frontiers in microbiology·2026

Same author

sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension.

The European respiratory journal·2026

Same author

Triglyceride-glucose body mass index and risk of incident venous thromboembolism: a prospective cohort study from the UK Biobank.

European journal of medical research·2026

Search research articles

Related Experiment Video

Updated: Dec 24, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Beta-blockers in COPD: A systematic review based on recent research.

Xiao-Fang Li¹, Yi-Min Mao¹

¹Department of Respiratory Medicine, The First Affiliated Hospital/College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan Province, China.

|April 11, 2020

Summary

Beta-blockers are often avoided in chronic obstructive pulmonary disease (COPD) patients with heart issues. However, recent randomized trials suggest they may improve outcomes and reduce mortality in COPD patients.

Keywords:

Beta-blockers COPD Systematic review

More Related Videos

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Dec 24, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Published on: May 30, 2025

Area of Science:

Cardiology
Pulmonology
Pharmacology

Background:

Cardiovascular complications are frequent in patients with chronic obstructive pulmonary disease (COPD).
Beta-blockers are typically underutilized in COPD patients due to concerns about potential bronchospasm.
Observational data suggest potential benefits of beta-blockers in COPD, but robust clinical trial evidence is limited.

Purpose of the Study:

To review the current evidence on the application of beta-blockers in patients diagnosed with chronic obstructive pulmonary disease.
To analyze the findings from recent randomized controlled trials (RCTs) regarding beta-blocker use in COPD.

Main Methods:

Systematic review of the latest published randomized controlled trials.
Analysis of studies investigating beta-blocker therapy in patients with COPD and cardiovascular comorbidities.

Main Results:

The review synthesizes data from recent RCTs, evaluating the efficacy and safety of beta-blockers in COPD patients.
Evidence regarding the impact of beta-blockers on disease progression and mortality in this population is critically examined.

Conclusions:

The findings provide an updated perspective on the role of beta-blockers in managing COPD patients with cardiovascular disease.
This review aims to guide clinical practice by clarifying the benefits and risks based on high-quality trial data.